New drug aims to stop repeat heart attacks by calming inflammation
NCT ID NCT07276282
First seen Dec 31, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests a drug called ziltivekimab in people who recently had a heart attack. The goal is to see if it can reduce dangerous fatty plaques in the arteries by lowering inflammation. About 332 participants will receive either the drug or a placebo, plus standard care, for 15 months. Special imaging will measure changes in plaque buildup.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bern University Hospital, Inselspital Bern
RECRUITINGBern, Switzerland
Contact
Conditions
Explore the condition pages connected to this study.